Interestingly, PARPi resistance can be reversed with a small molecule inhibitor P1-B that suppresses the U2 snRNP spliceosome machinery, leading to a silencing of the splicing event responsible for generating BRCA1-∆11q and re-sensitization of cancer cells to PARPi treatment [125]. Here, BRCA1 is linked to cancer.